Stephen T. Barclay

2.4k total citations
79 papers, 1.2k citations indexed

About

Stephen T. Barclay is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Stephen T. Barclay has authored 79 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hepatology, 51 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in Stephen T. Barclay's work include Hepatitis C virus research (54 papers), Liver Disease Diagnosis and Treatment (41 papers) and Hepatitis B Virus Studies (23 papers). Stephen T. Barclay is often cited by papers focused on Hepatitis C virus research (54 papers), Liver Disease Diagnosis and Treatment (41 papers) and Hepatitis B Virus Studies (23 papers). Stephen T. Barclay collaborates with scholars based in United Kingdom, United States and Ireland. Stephen T. Barclay's co-authors include John Dillon, Peter Hayes, Andrew Fraser, Sharon Hutchinson, David Goldberg, John M. Thomason, Jeffrey R. Idle, R. A. Seymour, Hamish Innes and Peter R. Mills and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gastroenterology.

In The Last Decade

Stephen T. Barclay

70 papers receiving 1.1k citations

Peers

Countries citing papers authored by Stephen T. Barclay

Since Specialization

Citations

This map shows the geographic impact of Stephen T. Barclay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen T. Barclay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen T. Barclay more than expected).

Fields of papers citing papers by Stephen T. Barclay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen T. Barclay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen T. Barclay. The network helps show where Stephen T. Barclay may publish in the future.

Co-authorship network of co-authors of Stephen T. Barclay

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen T. Barclay. A scholar is included among the top collaborators of Stephen T. Barclay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen T. Barclay. Stephen T. Barclay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study 2025 ·The American Journal of Gastroenterology ·Christopher L. Bowlus, Douglas Thorburn, Stephen T. Barclay, Deepak Joshi, María‐Carlota Londoño, Parvez Mantry, Rifaat Safadi, Revital Aricha, (unknown), Matthew Frankel, John Lawler, Ilan Vaknin, Adi Mor, (unknown)	0
2	Occult hepatitis B virus infection: risk for a blood supply, but how about individuals’ health? 2025 ·EClinicalMedicine ·Michael X. Fu, Ahmed M Elsharkawy, Brendan Healy, Celia Jackson, Daniel Bradshaw, (unknown), Ines Ushiro‐Lumb, (unknown), (unknown), Kathryn Maguire, Monica Desai, Neil McDougall, Nicole Priddee, Stephen T. Barclay, (unknown), Peter Simmonds, William L. Irving, Heli Harvala	0
3	Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study 2023 ·BMJ Open Gastroenterology ·Alistair S. McLaren, (unknown), Douglas Cartwright, (unknown), Stephen T. Barclay, Matthew Priest, (unknown), (unknown), (unknown), Adrian J. Stanley, T.R. Jeffry Evans	0
4	Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment 2022 ·Viruses ·Rajiv Shah, Stephen T. Barclay, (unknown), Ray Fox, Rory Gunson, Amanda Bradley-Stewart, Samantha J. Shepherd, Alasdair Maclean, L. Tong, (unknown), (unknown), Ana da Silva Filipe, Emma C. Thomson, Christopher Davis	1
5	Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making 2022 ·SHILAP Revista de lepidopterología ·Hamish Innes, Philip J. Johnson, Scott McDonald, (unknown), Alan C. Yeung, John Dillon, Peter Hayes, April Went, Stephen T. Barclay, Andrew Fraser, Andrew Bathgate, David Goldberg, Sharon Hutchinson	3
6	Hepatocellular Carcinoma Risk Scores Predict Patients Under Surveillance at Low Risk of Benefit and High Risk of Harm 2022 ·Digestive Diseases and Sciences ·(unknown), Matthew Priest, (unknown), Ewan Forrest, Adrian J. Stanley, Stephen T. Barclay	6
7	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale‐up of direct‐acting anti‐viral therapy in community drug services: real‐world data 2021 ·Addiction ·Norah Palmateer, Andrew McAuley, John Dillon, Scott McDonald, Alan C. Yeung, (unknown), Stephen T. Barclay, Peter Hayes, Samantha J. Shepherd, Rory Gunson, David Goldberg, Matthew Hickman, Sharon Hutchinson	26
8	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection 2021 ·JHEP Reports ·Hamish Innes, Peter Jepsen, Scott McDonald, John Dillon, (unknown), Alan C. Yeung, (unknown), April Went, Andrew Fraser, Andrew Bathgate, M. Azim Ansari, Stephen T. Barclay, David Goldberg, Peter Hayes, Philip J. Johnson, Eleanor Barnes, William L. Irving, Sharon Hutchinson, Indra Neil Guha	17
9	Real‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype 2020 ·Journal of Viral Hepatitis ·Kevin G. Pollock, Scott McDonald, Rory Gunson, Allan McLeod, April Went, David Goldberg, Sharon Hutchinson, Stephen T. Barclay	8
10	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study 2020 ·Gut ·Sharon Hutchinson, Heather Valerio, Scott McDonald, Alan C. Yeung, Kevin G. Pollock, (unknown), Stephen T. Barclay, John Dillon, Raymond G. Fox, Peter Bramley, Andrew Fraser, N. Kennedy, Rory Gunson, Kate Templeton, Hamish Innes, Allan McLeod, Amanda Weir, Peter Hayes, David Goldberg	19
11	Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis 2019 ·Journal of Viral Hepatitis ·Alison Boyle, Fiona Marra, (unknown), (unknown), T. Ritchíe, Matthew Priest, Mathis Heydtmann, Stephen T. Barclay	4
12	Insights into frequent asthma exacerbations from a primary care perspective and the implications of UK National Review of Asthma Deaths recommendations 2018 ·npj Primary Care Respiratory Medicine ·(unknown), Rekha Chaudhuri, Neil C. Thomson, Nitish Ramparsad, (unknown), Stephen T. Barclay, Seán MacBride‐Stewart, (unknown), (unknown), Charles McSharry, (unknown), Malcolm Shepherd, (unknown)	24
13	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen 2017 ·Journal of Hepatology ·Hamish Innes, Stephen T. Barclay, Peter Hayes, Andrew Fraser, John Dillon, Adrian J. Stanley, (unknown), Scott McDonald, David Goldberg, Heather Valerio, Ray Fox, N. Kennedy, P. Bramley, Sharon Hutchinson	77
14	Factors associated with spontaneous clearance of chronic hepatitis C virus infection 2016 ·Journal of Hepatology ·Naomi Bulteel, (unknown), Ewan Forrest, Adrian J. Stanley, Hamish Innes, Peter R. Mills, Heather Valerio, Rory Gunson, Celia Aitken, (unknown), Ray Fox, Stephen T. Barclay	46
15	Tracking TCRβ Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region 2016 ·Frontiers in Immunology ·Mark W. Robinson, Joseph Hughes, Gavin S. Wilkie, (unknown), Stephen T. Barclay, Peter R. Mills, Arvind H. Patel, Emma C. Thomson, John McLauchlan	2
16	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population 2016 ·Journal of Hepatology ·Hamish Innes, Scott McDonald, Peter Hayes, John Dillon, (unknown), David Goldberg, Peter R. Mills, Stephen T. Barclay, David Wilks, Heather Valerio, Ray Fox, (unknown), N. Kennedy, Judith Morris, Andrew Fraser, Adrian J. Stanley, Peter Bramley, Sharon Hutchinson	38
17	Review article: 2014 UK consensus guidelines – hepatitis C management and direct‐acting anti‐viral therapy 2014 ·Alimentary Pharmacology & Therapeutics ·Michael H. Miller, Kosh Agarwal, (unknown), Ashley Brown, Stephen T. Barclay, (unknown), Geoffrey Dusheiko, Graham R. Foster, Ray Fox, Peter Hayes, Clifford Leen, (unknown), Stephen Ryder, (unknown), Andrew Ustianowski, John Dillon	31
18	PTU-093 Hcc Diagnosed on Surveillance Programmes: impact on Stage and outcome 2013 ·Gut ·Alia Ahmed, Zia Ul Mustafa, (unknown), Mark J. Rutherford, S Ballantyne, Raj S. Kasthuri, Jonathan Evans, Ewan Forrest, Stephen T. Barclay, (unknown), (unknown), (unknown), Adrian J. Stanley	1
19	Transient elastography as a predictor of oesophageal varices, a comparison with other non invasive markers: Table 1 2011 ·Gut ·Elizabeth Reed, Adrian J. Stanley, Ewan Forrest, (unknown), (unknown), (unknown), Stephen T. Barclay	2
20	The incidence and severity of nifedipine‐induced gingival overgrowth 1992 ·Journal Of Clinical Periodontology ·Stephen T. Barclay, John M. Thomason, Jeffrey R. Idle, R. A. Seymour	146

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact